REG - Avacta Group PLC - AVA6000 data poster presentation at AACR

AvactaAnnouncement

29/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220329:nRSc3105Ga&default-theme=true

RNS Number : 3105G  Avacta Group PLC  29 March 2022

29 March 2022

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Avacta to present pre-clinical data on AVA6000 at the American Association for
Cancer Research Annual Meeting

 

Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer
of powerful diagnostics based on its innovative Affimer(®) and pre|CISION™
platforms, announces it will present a poster entitled 'AVA6000, a novel
precision medicine, targeted to the tumor microenvironment via Fibroblast
Activation Protein (FAP) mediated cleavage', at the American Association for
Cancer Research (AACR) 2022 Annual Meeting, taking place at Ernest N. Morial
Convention Center, New Orleans, Louisana between 8-13 April.

 

The poster describes the pre-clinical rationale for the company's leading
oncology candidate, AVA6000, a FAP (fibroblast activation protein α)
activated doxorubicin therapeutic. AVA6000 utilises Avacta's pre|CISION™
platform to improve the safety and therapeutic index of doxorubicin. AVA6000
has been designed to limit cell penetration of the drug, and therefore its
cell killing effect, until it is specifically activated FAP, which is in high
concentration in many solid tumours compared with healthy tissues. The
resulting reduced exposure of healthy tissues to active doxorubicin has the
potential to significantly increase its therapeutic index by reducing the
incidence of adverse effects, including cardiotoxicity and myelosuppression. A
first-in-human Phase I clinical trial (ALS-6000-101) has been initiated in the
UK in a broad spectrum of high FAP expressing tumours.

 

Poster presentation Title: AVA6000, a novel Precision medicine, targeted to
the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated
cleavage.

Session Category: Experimental and Molecular Therapeutics

Session Title: Drug Targets

Session Date and Time: Monday Apr 11, 2022 1:30 PM - 5:00 PM CT

Location: New Orleans Convention Center, Exhibit Halls D-H

Abstract Number: #1815

Presenter: Fiona McLaughlin, PhD, Chief Scientific Officer and Neil Bell,
Chief Development Officer, Avacta Life Sciences Ltd.

 

The abstract is available via the AACR annual meeting website, here:
https://www.aacr.org/meeting/aacr-annual-meeting-2022/abstracts/
(https://www.aacr.org/meeting/aacr-annual-meeting-2022/abstracts/)

 

Copies of the poster will be available on Avacta's website following the
conference at: https://avacta.com/investors/documents-presentations/
(https://avacta.com/investors/documents-presentations/)

 

 

ENDS

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                              Tel: +44 (0) 844 414 0452

 Alastair Smith, Chief Executive Officer                       www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)             Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Fred Walsh / Nicholas Harland   www.stifel.com (http://www.stifel.com/)

 FTI Consulting (Financial Media and IR)                       Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw                                      Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                Tel: +44 (0)7891 477 378

 Lily Jeffery                                                  lily.jeffery@zymecommunications.com

                                                             (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com)

 

Avacta Group is developing novel cancer immunotherapies and powerful
diagnostics based on its two proprietary platforms - Affimer(®) biologics and
pre|CISION™ tumour targeted chemotherapies.

 

The Affimer(®) platform is an alternative to antibodies and is derived from a
small human protein. Affimer technology has been designed to address many of
the negative issues of antibodies, principally: the time taken to generate new
antibodies, the reliance on an animal's immune response; poor specificity in
many cases; in addition to, the complexity and high cost of manufacture.
Despite these shortcomings, antibodies currently dominate markets, such as
diagnostics and therapeutics, which are worth in excess of $100bn.

 

Avacta's pre|CISION™ targeted chemotherapy platform is designed to
selectively release active chemotherapy in FAP rich tumour tissue to limit the
systemic exposure that causes damage to healthy tissues, and thereby aims to
improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

The Avacta Group comprises two divisions: The therapeutics development
activities are based in London and Cambridge, UK and a separate diagnostics
business unit is based in Wetherby, UK. The Group is generating near-term
revenues from Affimer(®) reagents for diagnostics, bioprocessing and
research.

 

Avacta's Diagnostics Division is developing an in-house pipeline of
Affimer-based diagnostic assays, including the AffiDX(®) SARS-CoV-2 Lateral
Flow Rapid Antigen Test, and works with partners world-wide to develop bespoke
Affimer(®) reagents for third party products.

 

Avacta's Therapeutics Division is working to generate more tolerable and
durable treatments for oncology patients who do not respond to existing
therapies. By combining its two proprietary platforms the Group is building a
wholly owned pipeline of clinically differentiated cancer therapies. In 2021
Avacta transitioned to become a clinical stage biopharmaceutical company, when
it commenced a phase I trial in patients with locally advanced or metastatic
selected solid tumours. The study was a first-in-human, open label,
dose-escalation and expansion study of the Group's lead pre|CISION™ prodrug,
AVA6000 (a pro-doxorubicin).

 

Avacta has established drug development partnerships with pharma and biotech,
including a multi-target deal with LG Chem worth up to $400m, a joint venture
in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies
incorporating Affimer immune-modulators and a recent license agreement with
Point Biopharma for them to develop radiopharmaceuticals based on the
pre|CISION™ platform.

 

To register for news alerts by email go
to www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBCGDXIUDDGDI